ETC-1002

Esperion Therapeutics

Esperion Therapeutics Presents Promising Test Results On Cholesterol Drug

The pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today’s cholesterol-lowering statin drugs.

WWJ Newsradio 950–11/18/2013

esperion

Esperion Starts Next Phase Of Cholesterol Drug Trial

The Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.

WWJ Newsradio 950–10/30/2013

Esperion Gets Positive Results From New Study Of Cholesterol Drug

Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.

WWJ Newsradio 950–06/09/2013

esperion

Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New Drug

Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

WWJ Newsradio 950–05/02/2013

Follow

Get every new post delivered to your Inbox.

Join 1,974 other followers